Overview of diabetic foot; novel treatments in diabetic foot ulcer

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 1-6

  Larijani, B ^a   Hasani Ranjbar, S ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ANGIPARS ; Diabetic foot ulcer; Overview; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR STIMULATING AGENT; ANGIPARS; ANTIINFECTIVE AGENT; BECAPLERMIN; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HERBACEOUS AGENT; IMMUNOSTIMULATING AGENT; IODINE; NITRIC OXIDE DONOR; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; RETINOIC ACID; SEMELIL; UNCLASSIFIED DRUG; VASOACTIVE AGENT; WARFARIN; ZINC;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTIBIOTIC THERAPY; ARTERY DISEASE; ARTIFICIAL SKIN; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION THERAPY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DRUG EFFICACY; ELECTROSTIMULATION; FOOT AMPUTATION; FOOT INFECTION; FOOT INJURY; FOOT MALFORMATION; FOOT ULCER; GENE THERAPY; HUMAN; HYDROGEL; HYGIENE; HYPERBARIC OXYGEN; INFECTION; INFECTION CONTROL; INFECTION SENSITIVITY; MAGGOT THERAPY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATIENT EDUCATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVASCULARIZATION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WOUND DRESSING; WOUND HEALING; ZINC BLOOD LEVEL;

EID: 38949121628     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Sicree R,Shaw j,Zimmet p. Diabetes and impaired glucose tolerance. In: Delice Gan. Diabetes Atlas. 3th edition. International Diabetes Federation 2006; 51
2. Abol Hassani F, Mohajeri Tehrani MR, Tabatabaei O, Larijani B. Burden of diabetes and its complications in Iran in year 2000 Iran J Diabetes and Lipid Disord 2005; 5:35-48
3. Larijani B, Forouzandeh F. Diabetic foot disorders. Iran J Diabetes and Lipid Disord 2003;2(2):103-93
4. Larijani B, Afshari M, Bastan Hagh MH, Pajouhi M, Baradar Jalili R, Moadi M Prevalence of lower limb amputation in patients with diabetic foot ulcer in Imam Khomeini and Shariati hospitals, 1979-2001 J Med COUNCIL Islam Repub Iran 2005;1(23): 29-25
5. Larijani B, Afshari M, Bastan Hagh MH, Pajouhi M, Baradar Jalili R, Moadi M. Lower limb amputation in patients with diabetic foot ulcer.A 22 year review. MJIRC 2006;8(3):21-24
6. Fard AS, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract. 2007 Nov; 61(11):1931-8.
7. Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998;20(1):169-81
8. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994 Sep 29;331(13):854-60
9. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998 May;21(5):855-9
10. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomedicine & Pharmacotherapy 2005; 59(7): 365-373
11. David K McCulloch. Management of diabetic foot lesions. Up-To-Date 2007 version 15.2
12. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurology 2005,10(5):24
13. Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.
14. Larijani B, Shooshtarizadeh P, Mosaffa N, Heshmat R . Polymorphonuclear leucocyte respiratory burst activity correlates with serum zinc level in type 2 diabetic patients with foot ulcers. Br J Biomed Sci. 2007;64(1):13-7
15. Gough, A, Clapperton, M, Rolando, N, et al. Randomized placebo-controlled trial of granulocyte colony-stimulating factor in diabetic foot infection. Lancet 1997; 350:855.
16. de Lalla, F, Pellizzer, G, Strazzabosco, M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45:1094.
17. Yonem, a, Cakir, B, Guler, S, et al. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3:332.
18. Kastenbauer, T, Hornlein, B, Sokol, G, Irsigler, K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46:27.
19. Cruciani, M, Lipsky, BA, Mengoli, C, de Lalla, F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections: A meta-analysis. Diabetes Care 2005; 28:454.
20. Hogge J, Krasner D, Nguyen H, Harkless LB, Armstrong DG. The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. J Am Podiatr Med Assoc 2000;90:57-65
21. Smith, J. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev 2002; CD003556.
22. Hanna, GP, Fujise, K, Kjellgren, O, et al. Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: Importance of aggressive interventional approach and roles of transcutaneous oximetry. J Am Coll Cardiol 1997; 30:664.
23. Wieman, TJ, Smiell, JM, Su, Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21:822.
24. Tsang, MW, Wong, WK, Hung, CS, Lai, KM. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26:1856.
25. Larijani B, Afshari M, Fadaei M, Pajouhi M, Bastan Hagh MH, Baradar Jalili R Effect of local epidermal growth factor on wound healing in diabetic foot. Iran J Diabetes and Lipid Disord 2003; 18(5): 110-107
26. Tom, WL, Peng, DH, Allaei, A, et al. The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol 2005; 141:1373.
27. Veves, A, Falanga, V, Armstrong, DG, Sabolinski, ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Apligraf Diabetic Foot Ulcer Study. Diabetes Care 2001; 24:290.
28. Leslie, CA, Sapico, FL, Ginunas, VJ, et al. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988; 11:111.
29. Faglia, E, Favales, F, Aldeghi, A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcers: a randomized study. Diabetes Care 1996; 19:1338.
30. Muthukumarasamy, MG, Sivakumar, G. Manoharan, G. Topical phenytoin in diabetic foot ulcers. Diabetes Care 1991; 14:909.
31. Akbari A, Moodi H, Ghiasi F, Sagheb HM, Rashidi H. Effects of vacuum-compression therapy on healing of diabetic foot ulcers: Randomized controlled trial. J Rehabil Res Dev 2007;44(5):631-6
32. Frykberg RG, Williams DV. Negative-pressure wound therapy and diabetic foot amputations: a retrospective study of payer claims data. J Am Podiatr Med Assoc. 2007; 97(5):351-9.
33. Baker, LL, Chambers, R, DeMuth, SK, et al. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997; 20:405.
34. Blackman, JD, Senseng, D, Quinn, L, et al. Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers. Diabetes Care 1994; 17:322.
35. Marston, WA, Hanft, J, Norwood, P, Pollak, R. The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers: Results of a prospective randomized trial. Diabetes Care 2003; 26:1701.
36. Petrova N, Edmonds M. Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov; 11(4):709-24
37. Abdollahi M, Farzamfar B, Salary P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Rodent acute and sub-chronic toxicity evaluation of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing. DARU 2008; 16(suppl.1): 7-14.
38. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A, Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. DARU 2008; 16(suppl.1): 15-19.
39. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salary P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU 2008; 16(suppl.1): 20-24.
40. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial. DARU 2008; 16(suppl.1): 25-30.
41. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer: A phase 2 clinical study. DARU 2008; 16(suppl.1): 31-34.
42. Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M, Gharibdoust F, Madani SH. Effects of Intravenous Semelil (ANGIPARS™) on Diabetic Foot Ulcers Healing: A Multicenter Clinical Trial. DARU 2008; 16(suppl.1): 35-40.
43. Bahrami A, Kamali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorram HR, Gharibdoust F, Madani SH, Larijani B. Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial. DARU 2008; 16(suppl.1): 41-48.